Literature DB >> 20591215

Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK.

Qi-Jing Wang1, Hui Wang, Ke Pan, Yong-Qiang Li, Li-Xi Huang, Shi-Ping Chen, Jia He, Miao-La Ke, Jing-Jing Zhao, Jian-Jun Li, Jian-Cong Sun, Xiao-Ting Liang, Hai-Qing Ma, Yi-Bing Chen, Jian-Chuan Xia.   

Abstract

BACKGROUND AND
OBJECTIVE: Cytokine-induced killer (CIK) cells and autologous dendritic cells-CIK (DC-CIK) cells co-cultured with autologous dendritic cells (DCs) and CIK cells are commonly used for immunotherapy recently. We compared the anti-tumor immune response of CIK cells, autologous DC-CIK cells, and semi-allogeneic DC-CIK cells to explore a more effective anti-tumor adoptive immunotherapy approach.
METHODS: Peripheral monocytes were isolated from patients with renal carcinoma, lung cancer, or maxillary squamous cell carcinoma and their healthy adult children. Isolated cells were cultured and induced as DCs and CIK cells in vitro. CIK cells from patients were co-cultured with autologous DCs and DCs from their children respectively, generating DC-CIK cells and semi-allogeneic DC-CIK cells. The anti-tumor activities of autologous CIK cells, autologous DC-CIK cells, and semi-allogeneic DC-CIK cells were measured by LDH assay. Intracellular staining was used to test the secretion of cytokines. Flow cytometry was applied for detecting the phonotype changes of these three types of cells. Cell proliferation and cell apoptosis were detected by 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE) and Annexin V/PI respectively.
RESULTS: Compared with autologous CIK cells and DC-CIK cells, semi-allogeneic DC-CIK cells significantly enhanced the anti-tumor activity and IFN-gamma secretion, reduced IL-4 secretion, increased the ratio of CD3(+)CD56(+) cells and CD3(+)CD8(+) cells, decreased the number of CD4(+)CD25(+) cells, promoted cell proliferation, and lessened cell apoptosis.
CONCLUSIONS: Semi-allogeneic DC-CIK cells had a stronger anti-tumor effect than did autologous CIK cells and DC-CIK cells. Our results provided experimental evidence for clinical application of DC-CIK cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20591215     DOI: 10.5732/cjc.009.10772

Source DB:  PubMed          Journal:  Chin J Cancer        ISSN: 1944-446X


  18 in total

1.  Comparative study of different procedures for the separation of peripheral blood mononuclear cells in cytokine-induced killer cell immunotherapy for hepatocarcinoma.

Authors:  Hui Liu; Jianyu Li; Fengmei Wang; Yingtang Gao; Ying Luo; Peng Wang; Chenglong Li; Zhengyan Zhu
Journal:  Tumour Biol       Date:  2014-11-24

2.  Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.

Authors:  Jun Ren; William R Gwin; Xinna Zhou; Xiaoli Wang; Hongyan Huang; Ni Jiang; Lei Zhou; Pankaj Agarwal; Amy Hobeika; Erika Crosby; Zachary C Hartman; Michael A Morse; Kevin H Eng; H Kim Lyerly
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

3.  Effects of dendritic cell-activated and cytokine-induced killer cell therapy on 22 children with acute myeloid leukemia after chemotherapy.

Authors:  Yan Bai; Jin-E Zheng; Nan Wang; He-Hua Cai; Li-Na Zhai; Yao-Hui Wu; Fang Wang; Run-Ming Jin; Dong-Feng Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

4.  Cytokine-induced killer cells combined with dendritic cells inhibited liver cancer cells.

Authors:  Qi-Ying Li; Yang Shi; De-Hong Huang; Tao Yang; Jiang-Hong Wang; Guo-He Yan; Hong-Yu Wang; Xian-Jun Tang; Chun-Yan Xiao; Wen-Jun Zhang; Man Zhang; Li Wang; Yi Gong; Wei Yang; Xian-Yu Wu; Ying Xiang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 5.  Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application.

Authors:  Yiming Meng; Zhifu Yu; Yefeng Wu; Tianzhao Du; Shi Chen; Fanjuan Meng; Nan Su; Yushu Ma; Xiaoxi Li; Sulan Sun; Guirong Zhang
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

6.  Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study.

Authors:  Ying Qiu; Mark M Yun; Ming Bao Xu; Yi Zhong Wang; Sheng Yun
Journal:  Int J Clin Oncol       Date:  2012-07-31       Impact factor: 3.402

7.  Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors.

Authors:  Chang-Long Chen; Qiu-Zhong Pan; De-Sheng Weng; Chuan-Miao Xie; Jing-Jing Zhao; Min-Shan Chen; Rui-Qing Peng; Dan-Dan Li; Ying Wang; Yan Tang; Qi-Jing Wang; Zhi-Ling Zhang; Xiao-Fei Zhang; Li-Juan Jiang; Zi-Qi Zhou; Qian Zhu; Jia He; Yuan Liu; Fang-Jian Zhou; Jian-Chuan Xia
Journal:  Oncoimmunology       Date:  2018-01-10       Impact factor: 8.110

8.  Human leukocyte antigen-haploidentical donor-derived cytokine-induced killer cells are safe and prolong the survival of patients with advanced non-small cell lung cancer.

Authors:  Shiyong Wang; Hui Zhang; Chang Liu; Xue Jiao; Dijie Liu; Weili DU; Ying He; Zhe Zhang; Xiuyan Wu; Jialing Wang; Chunyan Liang; Lu Zhang; Shu Liu
Journal:  Oncol Lett       Date:  2014-09-24       Impact factor: 2.967

9.  Effectiveness of immune therapy combined with chemotherapy on the immune function and recurrence rate of cervical cancer.

Authors:  Bin Chen; Lifen Liu; Haiyan Xu; Yijin Yang; Ling Zhang; Fengchun Zhang
Journal:  Exp Ther Med       Date:  2015-01-26       Impact factor: 2.447

10.  Safety of in vitro amplified HLA-haploidentical donor immune cell infusions for childhood malignancies.

Authors:  Fei Zhang; Xiao-Fei Sun; Yong-Qiang Li; Zi-Jun Zhen; Hai-Xia Zheng; Jia Zhu; Qi-Jing Wang; Su-Ying Lu; Jia He; Juan Wang; Ke Pan; Rui-Qing Cai; Yan Chen; De-Sheng Weng; Fei-Fei Sun; Jian-Chuan Xia
Journal:  Chin J Cancer       Date:  2013-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.